Zevra SVP sells 3,000 shares under 10b5-1 plan

Zevra Therapeutics SVP, Finance & Corp Controller Timothy J. Sangiovanni reported a planned stock sale.

Accepted by SEC EDGAR 02/04/2026 - 04:27 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Zevra Therapeutics SVP, Finance & Corp Controller Timothy J. Sangiovanni reported a planned stock sale. On 02/03/2026, he sold 3,000 shares of Zevra Therapeutics common stock in open-market transactions at a weighted average price of $9.1827 per share.

The trades were executed in multiple lots at prices ranging from $8.93 to $9.52, and were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on 03/28/2025. After this sale, he directly beneficially owns 29,590 Zevra common shares.

Insider Trade Summary

Net Seller: 3,000 shares

Net Sell 1 txn

Insider Sangiovanni Timothy J.

Role SVP, Finance & Corp Controller

Sold 3,000 shs ($28K)

Share of Position Sold 9.2%

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$9.1827	$28K

Holdings After Transaction: Common Stock — 29,590 shares (Direct)

Holdings Before and After: Common Stock, 32,590 to 29,590 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Adoption date of referenced 10b5-1(c) plan is: 3/28/2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $8.93 to $9.52. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Zevra Therapeutics (ZVRA) report for Timothy J. Sangiovanni?

Zevra Therapeutics reported that SVP, Finance & Corp Controller Timothy J. Sangiovanni sold 3,000 shares of common stock on 02/03/2026. The weighted average sale price was $9.1827 per share across multiple trades, leaving him with 29,590 shares owned directly.

At what prices were the Zevra Therapeutics (ZVRA) shares sold in this Form 4 filing?

The shares were sold in multiple trades at prices ranging from $8.93 to $9.52 per share. The Form 4 reports a weighted average sale price of $9.1827 per share for the 3,000 shares sold under the disclosed trading plan.

How many Zevra Therapeutics (ZVRA) shares does Timothy J. Sangiovanni own after the reported sale?

After selling 3,000 shares, Timothy J. Sangiovanni directly beneficially owns 29,590 shares of Zevra Therapeutics common stock. This remaining ownership amount is reported in the Form 4 under the column for securities beneficially owned following the transaction on 02/03/2026.

Was the Zevra Therapeutics (ZVRA) insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states that the transaction was executed under a referenced Rule 10b5-1(c) trading plan. The footnote discloses that the adoption date of this trading plan was 03/28/2025, indicating the sale followed a pre-arranged instruction schedule.

Who is the insider involved in the Zevra Therapeutics (ZVRA) Form 4 and what is their role?

The insider is Timothy J. Sangiovanni, who serves as Zevra Therapeutics’ SVP, Finance & Corp Controller. The Form 4 identifies him as an officer of the company and reports his direct ownership and recent sale of common stock shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sangiovanni Timothy J.

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

1180 CELEBRATION BOULEVARD, SUITE 103

(Street)

CELEBRATION FL 34747

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance & Corp Controller

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		S(1)		3,000	D	$9.1827(2)	29,590	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 3/28/2025.

2. This transaction was executed in multiple trades at prices ranging from $8.93 to $9.52. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Timothy J. Sangiovanni	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.